Survival Data for 648 Patients with Osteosarcoma Treated at One Institution

Mankin, Henry J.; Hornicek, Francis J.; Rosenberg, Andrew E.; Harmon, David C.; Gebhardt, Mark C.

doi:10.1097/01.blo.0000145991.65770.e6

Cited by 161 publications

(117 citation statements)

References 74 publications

(87 reference statements)

Supporting

Mentioning

109

Contrasting

Order By: Relevance

“…Therefore, there is a clinical need to identify genetic markers that not only provide insight into the pathogenesis of OS, but also its metastasis. With the current treatment for OS, which includes wide resection and chemotherapy, the average 5-year diseasefree survival rate is 65-70% (Davis et al, 1994;Mankin et al, 2004). However, despite advances in chemotherapy and surgical techniques over the last three decades, there has not been any significant improvement in patient survival.…”

mentioning

confidence: 99%

Insulin-like growth factor binding protein 5 suppresses tumor growth and metastasis of human osteosarcoma

et al. 2011

View full text Add to dashboard Cite

Osteosarcoma (OS) is the most common primary malignancy of bone. There is a critical need to identify the events that lead to the poorly understood mechanism of OS development and metastasis. The goal of this investigation is to identify and characterize a novel marker of OS progression. We have established and characterized a highly metastatic OS subline that is derived from the less metastatic human MG63 line through serial passages in nude mice via intratibial injections. Microarray analysis of the parental MG63, the highly metastatic MG63.2 subline, as well as the corresponding primary tumors and pulmonary metastases revealed insulin-like growth factor binding protein 5 (IGFBP5) to be one of the significantly downregulated genes in the metastatic subline. Confirmatory quantitative RT-PCR on 20 genes of interest demonstrated IGFBP5 to be the most differentially expressed and was therefore chosen to be one of the genes for further investigation. Adenoviral mediated overexpression and knockdown of IGFBP5 in the MG63 and MG63.2 cell lines, as well as other OS lines (143B and MNNG/HOS) that are independent of our MG63 lines, were employed to examine the role of IGFBP5. We found that overexpression of IGFBP5 inhibited in vitro cell proliferation, migration and invasion of OS cells. Additionally, IGFBP5 overexpression promoted apoptosis and cell cycle arrest in the G1 phase. In an orthotopic xenograft animal model, overexpression of IGFBP5 inhibited OS tumor growth and pulmonary metastases. Conversely, siRNA-mediated knockdown of IGFBP5 promoted OS tumor growth and pulmonary metastases in vivo. Immunohistochemical staining of patient-matched primary and metastatic OS samples demonstrated decreased IGFBP5 expression in the metastases. These results suggest 1) a role for IGFBP5 as a novel marker that has an important role in the pathogenesis of OS, and 2) that the loss of IGFBP5 function may contribute to more metastatic phenotypes in OS.

show abstract

mentioning

confidence: 99%

Insulin-like growth factor binding protein 5 suppresses tumor growth and metastasis of human osteosarcoma

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Thereafter, there have been multiple recent studies which indicate that limb preservation is the norm is bone tumors. [11][12][13][14] Limb-salvage procedures can be divided into two groups: arthrodesis or arthroplasty. An arthrodesis is usually obtained using bone allografts [14], vascularised autografts [15] or both.…”

Section: Discussionmentioning

confidence: 99%

“…The median resection length was 15 cm (range 6-25): the longest resections were performed in distal femur (median 16 cm, range 12-25), followed be proximal femur (median 15 cm, range 6-25) proximal tibia (median 12 cm, range [7][8][9][10][11][12][13][14][15] . No extra reconstructive interventions were needed for soft tissue coverage in any patients.…”

Section: Surgical Resectionmentioning

confidence: 99%

Limb Salvage Surgery in Bone Tumors: A Retrospective Study of 50 Cases in a Single Center

Chauhan

Joshi

Chopra³

et al. 2013

Indian J Surg Oncol

View full text Add to dashboard Cite

Modular segmental replacement system (MSRS) is one of the options for Limb conservation surgery in bone tumors. The study analyses a single center experience of use of MSRS for limb conservation in cases of primary bone tumors. Retrospective analysis was done for a series of cases of limb salvage procedures done over a five year period. All Patients with bone tumors who underwent limb salvage procedures utilising MSRS prosthesis were included in the study. The patients' record were perused for pre operative staging; neoadjuvant therapy used, if any; surgical procedure done; follow-up for prosthesis related complications and overall survival achieved. Total of 50 cases studied,included 28 males and 22 females . Median age at diagnosis of 28 (10-73) years. Tumor localized in lower limb in 38 patients, and upper limb in 12 patients. Tumors were malignant in 28 patients (56 %) and benign in 22 (44 %). The most common diagnosis was osteosarcoma (21 patients (42 %)) . The median resection length was 15 cm (range 6-25). High grade tumors (grade 2a and 2b) was found in 27 of 29 cases(93.1 %) . 14 patients had prosthesis related complications. The mean follow-up was 5 years (range: 3-7). 42 patients of 50 were alive with the endoprosthesis at the last follow-up. Survival rate of prosthesis is 84 %. The modular segmental-replacement system prosthesis favoured by us in limb sparing surgery for bone tumors results in satisfactory results in terms of tumor control and limb function.

show abstract

“…OSA has a high tendency to metastatic spread, eighty percent of all metastases arise in the lungs, especially the periphery of the lungs. Metastatic OSA exhibits resistance to conventional chemotherapy (Bacci et al, 2008;Bielack et al, 2008;Harting et al, 2006;Hughes, 2009;Messerschmitt et al, 2009;Kager et al, 2003), more than 30% of them do not respond to chemotherapy (Mankin et al, 2004). Prognosis of non-metastatic OSA has improved dramatically since the invention of preoperative and postoperative chemotherapy in the 1970s.…”

Section: Introductionmentioning

confidence: 99%

Review of the Molecular Pathogenesis of Osteosarcoma

Hao²,

Wang³

et al. 2014

Asian Pacific Journal of Cancer Prevention

124

109

View full text Add to dashboard Cite

Treating the osteosarcoma (OSA) remains a challenge. Current strategies focus on the primary tumor and have limited efficacy for metastatic OSA. A better understanding of the OSA pathogenesis may provide a rational basis for innovative treatment strategies especially for metastases. The aim of this review is to give an overview of the molecular mechanisms of OSA tumorigenesis, OSA cell proliferation, apoptosis, migration, and chemotherapy resistance, and how improved understanding might contribute to designing a better treatment target for OSA.

show abstract

Survival Data for 648 Patients with Osteosarcoma Treated at One Institution

Cited by 161 publications

References 74 publications

Insulin-like growth factor binding protein 5 suppresses tumor growth and metastasis of human osteosarcoma

Insulin-like growth factor binding protein 5 suppresses tumor growth and metastasis of human osteosarcoma

Limb Salvage Surgery in Bone Tumors: A Retrospective Study of 50 Cases in a Single Center

Review of the Molecular Pathogenesis of Osteosarcoma

Contact Info

Product

Resources

About